CYP17 Inhibitors for Prostate Cancer Treatment – An Update

V.   M.   Moreira; J.   A.R.   Salvador; T.   S.   Vasaitis; V.   C.O.   Njar

doi:10.2174/092986708783955428

Abstract

It is almost 70 years since the discovery by Huggins et al. that androgens are essential for prostate cancer (PC) growth and progression, and there has been about 30 years experience using ketoconazole for PC theraphy. Since then we have come a long way in learning about the disease and developing new strategies to approach it, among which is cytochrome 17α-hydroxylase-C17,20-lyase (CYP17) inhibition. This review focuses on the efforts to find prospective CYP17 inhibitors, both steroidal and nonsteroidal, in the absence of a 3D structure of the enzyme. It covers almost 4 decades of literature with highlights on the most significant achievements in this area, providing insight into PC pathophysiology, management and treatment options.

Keywords: Cytochrome 17α-hydroxylase-C17,20-lyase, CYP17, androgens, Prostate Cancer, steroidal inhibitors, nonsteroidal inhibitors, ketoconazole, abiraterone